Skip to content

Comparing levetiracetam with Diazepam in Preventing Febrile Seizure

Comparing levetiracetam with Diazepam in Preventing Febrile Seizure in Children

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230126057236N1
Enrollment
142
Registered
2023-05-08
Start date
2022-12-22
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Simple febrile convulsions. Simple febrile convulsions

Interventions

Intervention 1: Intervention group: With the onset of a fever higher than 5.38 degrees Celsius, the patients in the Lotirastam group receive the oral drug Lotirastam at a dose of 20 mg per kilogram di

Sponsors

Yasouj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Months to 60 Months

Inclusion criteria

Inclusion criteria: Children between six months and five years who come to the hospital emergency room due to Febrile seizures well-educated and cooperative parents

Exclusion criteria

Exclusion criteria: Convulsions caused by meningitis or encephalitis or brain abscess Seizures lasting more than 15 minutes or repeated seizures Diazepam or levetiracetam is contraindicated History of neurodevelopmental disorder or previous neurological disease Kidney dysfunction

Design outcomes

Primary

MeasureTime frame
Seizure recurrences based on parental history. Timepoint: At the beginning of the study (before the start of the intervention) and 8 and 4 weeks after entering the study - drug consumption. Method of measurement: Number of seizure recurrences based on parental history.

Secondary

MeasureTime frame
Possible drug side effects. Timepoint: Week 8 and 16 after entering the study. Method of measurement: History of parents and clinical examination of the child.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTorab Ahmadi

Yasouj University of Medical Sciences

torab914@gmail.com+98 917 742 8873

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026